Skip to main content
. 2022 Sep 2;113(11):3912–3921. doi: 10.1111/cas.15539

FIGURE 3.

FIGURE 3

Kaplan‐Meier plots analysis showing progression‐free survival and overall survival for patients with grade 2 or ≥3 immune‐related adverse events (irAEs) (A, B), endocrine irAEs (C, D), and skin irAEs (E, F) who survived longer than 3 months